In an ever-changing global landscape, the veterinary vaccine adjuvant market has proven to be resilient, even amid the unpredictability of prevailing health and economic conditions. Showing robust growth, the market's fortitude is linked to the rising levels of pet ownership coupled with increasing incidence of animal diseases. The growing market offers an array of opportunities for stakeholders looking to tap into innovative trends and emerging growth drivers.
Companion animal populations worldwide are on the rise, and with these, so is the demand for effective animal healthcare solutions. Veterinary vaccine adjuvants play a pivotal role in enhancing the immune response against infectious diseases, contributing to overall animal health and public safety. Additionally, acknowledgement of the importance of livestock health for food security and the economy is adding momentum to the market, underscoring the need for efficacious veterinary vaccines.
Nevertheless, potential hindrances such as adjuvant toxicity and side effects should not be overlooked. This comprehensive market research report provides invaluable insights to successfully navigate this dynamic market and make informed business decisions.
The COVID-19 pandemic impacted the veterinary vaccine adjuvants market. It highlighted the adaptability and response of veterinary healthcare to an emerging infectious disease and its role in maintaining animal health and protecting human public health. The increasing adoption of companion animals has increased the demand for vaccines, thus positively impacting the market. For instance, according to the People's Dispensary for Sick Animals (PDSA) PAW report published in June 2021, 2.0 million people in the United Kingdom owned pets between March 2020 and May 2021. Similarly, as per the report published by Nederlandse Voedingsindustrie Gezelschapsdieren(NVG) in 2021, around 8.0% of Dutch households started keeping a pet during the pandemic, which was around 6.4% during 2020, and another 7.0% intended to keep a pet. Out of the 8.0% of households that took a pet into their home during the pandemic, 47.0% of the people chose a dog and 27.0% chose a cat. Thus, the market witnessed positive growth during the pandemic, and it is expected to maintain an upward trend over the forecast period.
The rising use of adjuvants in the vaccine, the increasing livestock population and their associated diseases, and the high incidence of various diseases are the major drivers for the market. The high incidence of various diseases is one of the key factors propelling the market's growth. For instance, as per the NCBI study published in September 2021, anemia is the most common condition in sow herds, especially during gestation. The condition occurs despite iron supplementation in feed and has been associated with an increased stillbirth rate. Similarly, as per the report published by the CDC in September 2021, Bovine Spongiform Encephalopathy (BSE) is one of the most prevalent chronic diseases among cattle in Canada. The report stated that the true prevalence of Bovine Spongiform Encephalopathy (BSE) in Canada was around 90.0%, which is higher than the prevalence of BSE in the United States (3.0-8.0 cases per million Canada and around 0.167 cases per million in the United States). As per the report published by the Government of Canada in April 2022, various avian species, turkeys, ducks/chickens, geese, and peafowls were infected by avian influenza in March 2022. The disease is spreading rapidly among all livestock species, owing to which the government is planning to adopt necessary steps to control the spread. Thus, such a high prevalence of diseases may propel the demand for veterinary vaccines adjuvants, which is expected to surge the market's growth over the forecast period.
The increasing livestock population and associated diseases are also boosting the market's growth. For instance, according to the report published by Statistics Canada in May 2022, farms in Canada reported 12.6 million total cattle in 2021, up from 12.5 million in the previous year. The percentage increase in milk cows, steers, and beef cows offset declines in heifers for slaughter, heifers for dairy herd replacement, heifers for beef herd replacement, and bulls. According to the research study published in the Infection Ecology & Epidemiology in September 2021, one of the most dangerous zoonotic diseases in the world is salmonellosis. Salmonella prevalence in animals and risk factors for increased transmission of salmonella spp. from animals to people were evident. Thus, owing to the increasing livestock population and associated diseases across the world, the market is expected to grow considerably over the forecast period.
However, high toxicity and side effects of adjuvants may hinder the market's growth over the forecast period.
Key Market Trends
Companion Animal Segment is Expected to Witness Considerable Growth During the Forecast PeriodGlobally, dog and cat ownership is gaining popularity, especially after the pandemic. Owning a pet reduces blood pressure, serum triglycerides, and cholesterol levels, which consequently reduces the negative physiological impact of stress on the cardiovascular system. Deep interactions with pets have a positive impact on the release of oxytocin, one of the body’s “feel-good' neurotransmitters, which is ideally very important for social bonding. Such an increase in the rate of pet ownership across the world is expected to boost the market's growth.
The increasing animal health expenditure by owners to ensure better diagnosis and treatment and increasing pet ownership are expected to positively impact the veterinary vaccine adjuvants market. For instance, as per the report published by the European Pet Food Industry (FEDIAF) in 2021, in the European Union, around 140.0 million pets were reported (including Switzerland and Norway), of which around 64.0 million were dogs and 76.0 million were cats. It also reported that France and Germany constitute the highest pet population, i.e., around 22,600,000 and 26,400,000, respectively. The report also indicated that cats are the leading pets in the European Union. Lithuania and Estonia comprise an equal balance of dog and cat populations. Spain shows more preference toward dogs, and their pet population surpasses the cat population by 3.0 million. According to the survey conducted by the Dibevoand the Dutch Food Industry Companion Animals (NVG) in 2021, around 25.0% of households owned a cat and around 20.0% owned a dog. Aquarium fish secured the third-highest position in terms of preferred pets, with more than 7.0%. Almost half of all Dutch households own one or more pets. The total number of pets in the Netherlands is estimated to be almost 27.0 million.
Vaccination is one of the essential requirements for companion animals. Thus, the increasing number of companion animals is expected to propel the demand for vaccines, thereby boosting the veterinary vaccine adjuvants market over the forecast period.
North America is Expected to Witness Significant Share During the Forecast PeriodNorth America is expected to witness considerable growth over the forecast period, owing to the rising adoption of companion animals, increasing pet healthcare insurance, and improved veterinary healthcare infrastructure. With the rising trends of diseases in North America, the associated use of veterinary vaccines is also increasing. For instance, as per the report published by the Government of Canada in April 2022, Bovine Spongiform Encephalopathy (BSE) is a progressive, fatal disease of the nervous system of cattle. Health Canada and the Canadian Food Inspection Agency (CFIA) responded to such challenges by developing a comprehensive set of internationally recognized, science-based measures that effectively minimize the likelihood of exposure, amplification, and spread of BSE within the cattle population and protect consumers from associated risks to human health. According to the NCBI research study published in September 2021, chronic wasting disease (CWD) is a highly prevalent prion disease affecting both wild and farmed animals and stands out for being highly contagious, widespread, and persistent in the environment and facilitating the transmission of the disease. Thus, such a high incidence of diseases is expected to propel the market's growth in North America.
Key product launches, high concentration of market players or manufacturers, acquisitions and partnerships among major players, and increasing pet ownership in the United States are some of the factors driving the growth of the veterinary vaccine adjuvants market in the country. According to the National Pet Owners Survey 2021-2022, conducted by the American Pet Products Association (APPA), around 70.0% of US households own a pet, which equates to 90.5 million homes, including 45.3 million cats and 69.0 million dogs. The rising adoption of pets may drive the growth of the veterinary vaccine adjuvants market in the longer term.
Competitive LandscapeThe veterinary vaccine adjuvant market is consolidated and consists of a few dominant players. In terms of market share, some of the major players currently dominate the market. With the rising prevalence of infectious diseases in animals, a few other smaller players are expected to enter the market in the coming years. Some of the major players in the market are SEPPIC, SPI Pharma, Bioveta AS, Croda Internation PLC, and Zoetis.
Additional benefits of purchasing the report:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
This product will be delivered within 2 business days.
Table of Contents
1.2 Scope of the Study
4.2 Market Drivers
4.2.1 Rising Use of Adjuvants in Vaccines
4.2.2 Increasing Livestock Population and Associated Diseases
4.2.3 High Incidence of Diseases
4.3 Market Restraints
4.3.1 High Toxicity and Side Effects of Adjuvants
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5.1.1 Alum and Calcium Salts
5.1.2 Oil Emulsion Adjuvants
5.1.3 Liposomes and Archaeosomes
5.1.4 Nanoparticles and Microparticles
5.1.5 Other Types
5.2 By Route of Administration
5.2.3 Other Routes of Administration
5.3 By Animal Type
5.3.2 Companion Animal
5.4 By Geography
5.4.1 North America
184.108.40.206 United States
220.127.116.11 United Kingdom
18.104.22.168 Rest of Europe
22.214.171.124 South Korea
126.96.36.199 Rest of Asia-Pacific
5.4.4 Middle East and Africa
188.8.131.52 South Africa
184.108.40.206 Rest of Middle East and Africa
5.4.5 South America
220.127.116.11 Rest of South America
6.1.1 Bioveta AS
6.1.2 Croda International PLC
6.1.3 Merck & Co. Inc.
6.1.4 Phibro Animal Health Corporation
6.1.6 SPI Pharma
6.1.9 OZ Biosciences
A selection of companies mentioned in this report includes:
- Bioveta AS
- Croda International PLC
- Merck & Co. Inc.
- Phibro Animal Health Corporation
- SPI Pharma
- OZ Biosciences